Literature DB >> 34734392

Dosing Psychedelics and MDMA.

Matthias E Liechti1,2, Friederike Holze3,4.   

Abstract

Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others. However, identifying proper doses is crucial. Controlled study data on dosing using well-characterized pharmaceutical formulations of the substances are scarce. The dose equivalence of different substances, dose-response effects, and subjective effects of different doses are of great interest and practically important for their clinical use in psychotherapy. Furthermore, the so-called microdosing of psychedelics has recently gained popularity, and the first placebo-controlled studies of LSD have been published. This chapter discusses different aspects of psychedelic dosing, including pharmaceutical aspects, definitions and characteristics of different doses, including microdoses, aspects of personalized dosing, and non-pharmacological factors, that can influence the response to psychedelics.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Dosing; Ego-dissolution dose; Good effect dose; Microdosing; Personalized medicine; Pharmacogenetics

Mesh:

Substances:

Year:  2022        PMID: 34734392     DOI: 10.1007/7854_2021_270

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  58 in total

1.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

2.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

3.  Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.

Authors:  Anya K Bershad; Katrin H Preller; Royce Lee; Sarah Keedy; Jamie Wren-Jarvis; Michael P Bremmer; Harriet de Wit
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-20

4.  Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.

Authors:  Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2019-06-03       Impact factor: 13.382

5.  Psychedelic Microdosing: Prevalence and Subjective Effects.

Authors:  Lindsay P Cameron; Angela Nazarian; David E Olson
Journal:  J Psychoactive Drugs       Date:  2020-01-23

6.  Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music.

Authors:  Frederick S Barrett; Katrin H Preller; Marcus Herdener; Petr Janata; Franz X Vollenweider
Journal:  Cereb Cortex       Date:  2018-11-01       Impact factor: 5.357

7.  Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.

Authors:  Randall T Brown; Christopher R Nicholas; Nicholas V Cozzi; Michele C Gassman; Karen M Cooper; Daniel Muller; Chantelle D Thomas; Scott J Hetzel; Kelsey M Henriquez; Alexandra S Ribaudo; Paul R Hutson
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

8.  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.

Authors:  Patrick C Dolder; Yasmin Schmid; Manuel Haschke; Katharina M Rentsch; Matthias E Liechti
Journal:  Int J Neuropsychopharmacol       Date:  2015-06-24       Impact factor: 5.176

9.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

10.  Neural correlates of the LSD experience revealed by multimodal neuroimaging.

Authors:  Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 12.779

View more
  2 in total

1.  Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.

Authors:  Friederike Holze; Laura Ley; Felix Müller; Anna M Becker; Isabelle Straumann; Patrick Vizeli; Sebastian Silva Kuehne; Marc A Roder; Urs Duthaler; Karolina E Kolaczynska; Nimmy Varghese; Anne Eckert; Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2022-02-25       Impact factor: 8.294

2.  Buddhist-like opposite diminishing and non-judging during ketamine infusion are associated with antidepressant response: an open-label personalized-dosing study.

Authors:  Kurt Stocker; Matthias Hartmann; Steffen Reissmann; Andreas Kist; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2022-07-25       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.